Table 3.

Thromboembolism, major bleeding, and all-cause inhospital death within 6 months after discharge in propensity score-matched patients treated with warfarin and DOACs

	1:4 Propensity score matched
	warfarin		DOACs		OR	95% CI	p value
	n = 557		n = 2,228
Recurrent VTE	42	(7.5%)	118	(5.3%)	0.69	(0.48–0.98)	0.043
Recurrent deep vein thrombosis	35	(6.3%)	97	(4.4%)	0.68	(0.46–1.01)
Recurrent pulmonary embolism	7	(1.3%)	29	(1.3%)	1.04	(0.45–2.38)
Major bleeding	6	(1.1%)	35	(1.6%)	1.47	(0.62–3.50)	0.39
Intracranial hemorrhage	1	(0.2%)	12	(0.5%)	3.01	(0.39–23.2)
Gastrointestinal bleeding	5	(0.9%)	17	(0.8%)	0.85	(0.31–2.31)
Other major bleeding	2	(0.4%)	6	(0.3%)	0.74	(0.15–3.72)
All-cause inhospital death	55	(9.9%)	248	(11.1%)	1.14	(0.84–1.56)	0.40
Composite outcomea	93	(16.7%)	376	(16.9%)	1.01	(0.79–1.30)	0.92

DOACs, direct oral anticoagulants; OR, odds ratio; CI, confidence interval.

^aComposite outcome, at least one of the following: recurrent VTE, major bleeding event, and all-cause inhospital death.